alexa Risk of Thromboembolism in Patients with Immune Thrombocytopenia

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Risk of Thromboembolism in Patients with Immune Thrombocytopenia

Immune thrombocytopenia (ITP) comprises a heterogeneous group of disorders characterized by autoimmune-mediated platelet destruction and impairment of platelet production [1,2]. Autoimmune-mediated accelerated platelet destruction with subsequent clearance in the reticuloendothelial (RE) system can be reduced by RE phagocytosis-preventing agents, such as intravenous immunoglobulin (IVIG), intravenous anti-D, or corticosteroids, or may be permanently resolved by splenectomy.

 

 

Citation: Takagi S, Suzuki I, Watanabe S (2015) Risk of Thromboembolism in Patients with Immune Thrombocytopenia. J Hematol Thrombo Dis 3:185. doi: 10.4172/2329-8790.1000185

 
  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger
 
adwords